Related Experiment Videos
[Biologic response modifiers in the treatment of solid tumors]
F Tagliaferri1, G Lucandri, F Stipa
1V Clinica chirurgica, Università La Sapienza, Roma.
Abstract:
This study concerns the clinical applications in Oncology of Biologic Response Modifiers; the authors focus the results reached in neoplasms, such as renal cell carcinoma or melanoma, whose sensitivity to this treatment has been proved. Prospective studies, published in 1990 have been reviewed, considering only those in which route and rate of response (complete and partial) were clearly specified. At present clinical efficacy concerning this topic is controversial and it probably depends on different reasons: immunogenicity of cancer, variable route of administration, lack of predictors. It should be stressed that more in depth studies about cancer immunology are required; a wide spread of immunotherapy will be feasible only by improving therapeutic strategies and limiting adverse effects of this treatment.
Insights
Biologic Response Modifiers show promise in treating cancers like renal cell carcinoma and melanoma. Further research into cancer immunology and optimized therapeutic strategies is needed to improve clinical efficacy and limit adverse effects.
Area of Science:
- Oncology
- Immunology
Context:
- Review of prospective studies from 1990 on Biologic Response Modifiers (BRMs) in cancer treatment.
- Focus on neoplasms like renal cell carcinoma and melanoma with proven sensitivity to BRMs.
- Inclusion criteria specified route and rate of response (complete and partial).
Purpose:
- To evaluate the clinical applications and efficacy of Biologic Response Modifiers in Oncology.
- To identify factors contributing to the controversial clinical efficacy of BRMs.
- To highlight the need for further research in cancer immunology.
Summary:
- Clinical efficacy of Biologic Response Modifiers remains controversial, potentially due to cancer immunogenicity, varied administration routes, and lack of predictive markers.
- Studies reviewed focused on specific cancers and response metrics.
- In-depth understanding of cancer immunology is crucial for advancing immunotherapy.
Impact:
- Suggests that improved therapeutic strategies and reduced adverse effects are necessary for wider immunotherapy adoption.
- Emphasizes the need for more research to overcome current limitations in BRM treatment.
- Highlights the potential of BRMs in specific oncological conditions.